Eisai Sues To Protect Popular Alzheimer's Treatment

Law360, New York (August 4, 2006, 12:00 AM EDT) -- A Tokyo-based drug company has filed a federal patent suit to protect its billion-dollar Alzheimer’s treatment Aricept ODT from generic competition.

The lawsuit was filed in federal court in New Jersey by Eisai Co. Ltd. and its U.S. subsidiary Eisai Inc. against Mutual Pharmaceutical Co. Ltd. and United Research Laboratories Inc.

At issue is U.S. Patent No. 4,895,841—which covers compounds used for the treatment of senile dementia, including donepezil hydrochloride, Aricept’s active ingredient. The ‘841 patent, which was issued in January 1990, is owned by Eisai...
To view the full article, register now.